| Objective: To explore the clinical effect of Kangfuyan capsule combined with azithromycin in the treatment of chronic pelvic inflammatory disease (CPID), so as to provide reference for clinicians to choose reasonable treatment scheme. Methods: A total of 100 patients with CPID treated in Shenyang International Travel Health Care Center during from January 2017 to December 2019 were selected as the research objects. According to the random number table method, the subjects were randomly divided into two groups: the control group and the study group (50 cases in each group). The control group was treated with azithromycin, and the study group was treated with Kangfuyan capsule and azithromycin. The clinical total effective rate and inflammatory factor levels of the two groups were compared. Results: The clinical total effective rate of the study group was 96.00%, which was higher than that of the control group (84.00%), and the difference was statistically significant (P＜0.05); there was no significant difference in the levels of C-reactive protein (CRP) and interleukin-2 (IL-2) between the two groups before treatment (P＞0.05), the CRP levels of two groups after treatment were lower than those before treatment, IL-2 levels were higher than those before the treatment, the difference was statistically significant (P＜0.05),the CRP level of the study group was lower than that of the control group, and the IL-2 level was higher than that of the control group (P＜0.05). Conclusion: In the treatment of patients with CPID, Kangfuyan capsule combined with azithromycin can improve the curative effect, promote the improvement of inflammation and facilitate the recovery of disease, which is worthy of recommendation. |
